Delving into the Latest Updates on TT-01488 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

BTK

Mechanism

BTK inhibitors(Tyrosine-protein kinase BTK inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [2]

Active Indication

B-Cell Malignant NeoplasmB-Cell LymphomaChronic Lymphocytic Leukemia+ [2]

Inactive Indication-

Originator Organization

TransThera Sciences (Nanjing), Inc.Startup

Active Organization

TransThera Sciences (Nanjing), Inc.Startup

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Primary objective: To determine the dose-limiting toxicity (DLT), recommended dose expansion (DRDE), and maximum tolerated dose (MTD) of TT-01488 (if applicable); Secondary objective: To evaluate the safety and tolerability, pharmacokinetics (PK), preliminary efficacy, and recommended phase II dose (RP2D) of TT-01488 (if applicable)

Start Date24 Mar 2023

Sponsor / Collaborator

TransThera Sciences (Nanjing), Inc.Startup

NCT05275504 / RecruitingPhase 1

A Phase I, First-In-Human, Multicenter, Open Label, and Dose-Escalation Study of TT-01488, Administered Orally in Adult Patients With B-Cell Malignancies

This is a first-in-human (FIH), multicenter, open-label Phase I dose escalation study to evaluate the safety and preliminary efficacy of the TT-01488 tablet, a non-covalent reversible BTK inhibitor, for the treatment of adult patients with B-cell malignancies.

Start Date01 Jun 2022

Sponsor / Collaborator

TransThera Sciences (Nanjing), Inc.Startup

100 Clinical Results associated with TT-01488

Login to view more data

100 Translational Medicine associated with TT-01488

Login to view more data

100 Patents (Medical) associated with TT-01488

Login to view more data

100 Deals associated with TT-01488

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
B-Cell Malignant Neoplasm	Phase 1	CN	TransThera Sciences (Nanjing), Inc.Startup	24 Mar 2023
B-Cell Lymphoma	Phase 1	US	TransThera Sciences (Nanjing), Inc.Startup	01 Jun 2022
Chronic Lymphocytic Leukemia	IND Approval	CN	TransThera Sciences (Nanjing), Inc.Startup	19 Apr 2022
Mantle-Cell Lymphoma	IND Approval	CN	TransThera Sciences (Nanjing), Inc.Startup	19 Apr 2022
Waldenstrom Macroglobulinemia	IND Approval	CN	TransThera Sciences (Nanjing), Inc.Startup	19 Apr 2022